How much revenue did BioArctic generate this year?
BioArctic has achieved a revenue of 1.02 B SEK this year.
BioArctic Revenue 2025
BioArctic Revenue
1.02 B SEK
Ticker
BIOA B.ST
ISIN
SE0010323311
WKN
A2H5GS
In 2025, BioArctic's sales reached 1.02 B SEK, a 278.38% difference from the 269.04 M SEK sales recorded in the previous year.
The BioArctic Revenue history
| YEAR | REVENUE (undefined SEK) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 6.79 | 8,33 |
| 2028e | 4.91 | 11,51 |
| 2027e | 2.82 | 20,05 |
| 2026e | 1.72 | 32,80 |
| 2025e | 1.02 | 55,51 |
| 2024e | 0.27 | 210,03 |
| 2023 | 0.62 | 91,73 |
| 2022 | 0.23 | 85,54 |
| 2021 | 0.02 | -7,37 |
| 2020 | 0.06 | 62,52 |
| 2019 | 0.28 | 88,94 |
| 2018 | 0.71 | 95,53 |
| 2017 | 0.14 | 74,27 |
| 2016 | 0.11 | 99,77 |
| 2015 | 0.04 | 100,00 |
BioArctic Revenue, EBIT, Net Income SE0010323311 · A2H5GS
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BioArctic, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioArctic from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioArctic’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BioArctic. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BioArctic’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BioArctic’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioArctic’s growth potential.
BioArctic Revenue, EBIT and net profit per share
| Date | BioArctic Revenue | BioArctic EBIT | BioArctic Net Income |
|---|---|---|---|
| 2029e | 6.79 B undefined | 5.85 B undefined | 3.87 B undefined |
| 2028e | 4.91 B undefined | 4.04 B undefined | 2.68 B undefined |
| 2027e | 2.82 B undefined | 2.05 B undefined | 1.37 B undefined |
| 2026e | 1.72 B undefined | 918.62 M undefined | 669.94 M undefined |
| 2025e | 1.02 B undefined | 332.05 M undefined | 228.25 M undefined |
| 2024e | 269.04 M undefined | -237.9 M undefined | -177.81 M undefined |
| 2023 | 616 M undefined | 264.58 M undefined | 229.25 M undefined |
| 2022 | 228.29 M undefined | -7.94 M undefined | -11.18 M undefined |
| 2021 | 23.15 M undefined | -140.74 M undefined | -119.79 M undefined |
| 2020 | 62.35 M undefined | -85.67 M undefined | -68.52 M undefined |
| 2019 | 281.77 M undefined | 111.09 M undefined | 88.47 M undefined |
| 2018 | 713.97 M undefined | 485.83 M undefined | 381.6 M undefined |
| 2017 | 140.71 M undefined | 19.29 M undefined | 15.16 M undefined |
| 2016 | 105.61 M undefined | 62.68 M undefined | 57.58 M undefined |
| 2015 | 41.57 M undefined | 4.82 M undefined | 3.71 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2015 | 41.57 M SEK | 4.82 M SEK | 3.71 M SEK |
| 2016 | 105.61 M SEK | 62.68 M SEK | 57.58 M SEK |
| 2017 | 140.71 M SEK | 19.29 M SEK | 15.16 M SEK |
| 2018 | 713.97 M SEK | 485.83 M SEK | 381.6 M SEK |
| 2019 | 281.77 M SEK | 111.09 M SEK | 88.47 M SEK |
| 2020 | 62.35 M SEK | -85.67 M SEK | -68.52 M SEK |
| 2021 | 23.15 M SEK | -140.74 M SEK | -119.79 M SEK |
| 2022 | 228.29 M SEK | -7.94 M SEK | -11.18 M SEK |
| 2023 | 616 M SEK | 264.58 M SEK | 229.25 M SEK |
| 2024e | 269.04 M SEK | -237.9 M SEK | -177.81 M SEK |
| 2025e | 1.02 B SEK | 332.05 M SEK | 228.25 M SEK |
| 2026e | 1.72 B SEK | 918.62 M SEK | 669.94 M SEK |
| 2027e | 2.82 B SEK | 2.05 B SEK | 1.37 B SEK |
| 2028e | 4.91 B SEK | 4.04 B SEK | 2.68 B SEK |
| 2029e | 6.79 B SEK | 5.85 B SEK | 3.87 B SEK |
BioArctic stock margins SE0010323311 · A2H5GS
The BioArctic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioArctic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioArctic.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BioArctic's sales revenue. A higher gross margin percentage indicates that the BioArctic retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BioArctic's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BioArctic's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioArctic's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioArctic. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioArctic's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BioArctic Margin History
| BioArctic Gross margin | BioArctic Profit margin | BioArctic EBIT margin | BioArctic Profit margin |
|---|---|---|---|
| 2029e | 91.73 % | 86.14 % | 57.05 % |
| 2028e | 91.73 % | 82.2 % | 54.59 % |
| 2027e | 91.73 % | 72.89 % | 48.78 % |
| 2026e | 91.73 % | 53.32 % | 38.88 % |
| 2025e | 91.73 % | 32.62 % | 22.42 % |
| 2024e | 91.73 % | -88.43 % | -66.09 % |
| 2023 | 91.73 % | 42.95 % | 37.22 % |
| 2022 | 85.54 % | -3.48 % | -4.9 % |
| 2021 | -7.37 % | -608.05 % | -517.54 % |
| 2020 | 62.52 % | -137.41 % | -109.9 % |
| 2019 | 88.94 % | 39.42 % | 31.4 % |
| 2018 | 95.53 % | 68.05 % | 53.45 % |
| 2017 | 74.27 % | 13.71 % | 10.77 % |
| 2016 | 99.77 % | 59.35 % | 54.52 % |
| 2015 | 100 % | 11.6 % | 8.92 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2015 | 100 % | 11.6 % | 8.92 % |
| 2016 | 99.77 % | 59.35 % | 54.52 % |
| 2017 | 74.27 % | 13.71 % | 10.77 % |
| 2018 | 95.53 % | 68.05 % | 53.45 % |
| 2019 | 88.94 % | 39.42 % | 31.4 % |
| 2020 | 62.52 % | -137.41 % | -109.9 % |
| 2021 | -7.37 % | -608.05 % | -517.54 % |
| 2022 | 85.54 % | -3.48 % | -4.9 % |
| 2023 | 91.73 % | 42.95 % | 37.22 % |
| 2024e | 91.73 % | -88.43 % | -66.09 % |
| 2025e | 91.73 % | 32.62 % | 22.42 % |
| 2026e | 91.73 % | 53.32 % | 38.88 % |
| 2027e | 91.73 % | 72.89 % | 48.78 % |
| 2028e | 91.73 % | 82.2 % | 54.59 % |
| 2029e | 91.73 % | 86.14 % | 57.05 % |
BioArctic Aktienanalyse
What does BioArctic do?
BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding BioArctic's Sales Figures
The sales figures of BioArctic originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing BioArctic’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize BioArctic's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in BioArctic’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about BioArctic stock
How much was the turnover of the company BioArctic compared to the previous year?
The revenue of BioArctic has increased by 278.38% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of BioArctic?
The revenue of BioArctic is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of BioArctic measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of BioArctic so important for investors?
The revenue of BioArctic is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does BioArctic pay?
Over the past 12 months, BioArctic paid a dividend of 1.5 SEK . This corresponds to a dividend yield of about 0.72 %. For the coming 12 months, BioArctic is expected to pay a dividend of 13.58 SEK.
What is the dividend yield of BioArctic?
The current dividend yield of BioArctic is 0.72 %.
When does BioArctic pay dividends?
BioArctic pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioArctic?
BioArctic paid dividends every year for the past 5 years.
What is the dividend of BioArctic?
For the upcoming 12 months, dividends amounting to 13.58 SEK are expected. This corresponds to a dividend yield of 6.48 %.
In which sector is BioArctic located?
BioArctic is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioArctic kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioArctic from 5/16/2019 amounting to 1.5 SEK, you needed to have the stock in your portfolio before the ex-date on 5/10/2019.
When did BioArctic pay the last dividend?
The last dividend was paid out on 5/16/2019.
What was the dividend of BioArctic in the year 2024?
In the year 2024, BioArctic distributed 0 SEK as dividends.
In which currency does BioArctic pay out the dividend?
The dividends of BioArctic are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioArctic
Our stock analysis for BioArctic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioArctic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
